NLRP3 and type 2 diabetes mellitus: Likewise, the relationship with the pathology of type 2 diabetes mellitus is treated using endothelial progenitor cells, finding that the expression of LOX-1 triggers the activation of the NLRP3 inflammasome as well as the inhibition of LOX-1 by drugs that suppress the activation of the inflammasome and therefore promotes the blockade of the adaptor protein ASC associated with apoptosis, which in turn leads to the cleavage and activation of caspase 1, whose domino effect cleaves il-1b precursors related to pathogenesis and vascular complication in type 2 diabetes mellitus [51].